@article{3118625,
    title = "Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review",
    author = "Kyriazoglou, A. and Kaparelou, M. and Goumas, G. and Liontos, M. and Zakopoulou, R. and Zografos, E. and Zygogianni, A. and Dimopoulos, M.A. and Zagouri, F.",
    journal = "Breast Care",
    year = "2022",
    volume = "17",
    number = "1",
    pages = "63-70",
    publisher = "S Karger AG",
    issn = "1661-3791, 1661-3805",
    doi = "10.1159/000514860",
    keywords = "anthracycline;  atezolizumab;  avelumab;  cemiplimab;  cyclophosphamide;  cytotoxic T lymphocyte antigen 4;  docetaxel;  doxorubicin;  durvalumab;  epidermal growth factor receptor 2;  immune checkpoint inhibitor;  ipilimumab;  nivolumab;  paclitaxel;  pembrolizumab;  pertuzumab;  progesterone;  programmed death 1 ligand 1;  programmed death 1 receptor;  rituximab;  ticilimumab;  trastuzumab;  trastuzumab emtansine;  utomilumab, biological therapy;  cancer growth;  cancer immunotherapy;  female;  hormonal therapy;  human;  human epidermal growth factor receptor 2 positive breast cancer;  neoadjuvant chemotherapy;  overall survival;  phase 2 clinical trial (topic);  phase 3 clinical trial (topic);  progression free survival;  randomized controlled trial (topic);  Review;  systematic review;  triple negative breast cancer;  tumor microenvironment",
    abstract = "Introduction: The clinical outcome of HER2-positive breast cancer patients changed with the use of anti-Her therapies, though it still remains an aggressive and fatal disease. Implementation of immune checkpoint inhibitors in HER2-positive Breast cancer is a concept supported by the reported biological and preclinical data. Methods: We conducted a systematic review of the current literature involving immune checkpoint inhibitors alone or in combination with targeted therapies or chemotherapy finalized or running in HER2-positive breast cancer. Results: Twelve clinical trials and 2 case reports were identified in our study. Conclusion: The reported clinical trials highlight that checkpoint inhibition seems to be promising in metastatic, neoadjuvant, and adjuvant settings of HER2-positive breast cancer. © 2021 S. Karger AG, Basel. Copyright: All rights reserved."
}